Renaissance Technologies LLC has recently announced that it has increased stake in Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) by 2.24%. After grabbing 13700.0 shares, the institutional investor is now in possession of 300.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.16% having worth around $9864.0.
Bellicum Pharmaceuticals Inc. (BLCM) concluded trading on 01/19/23 at a closing price of $1.20, with 0.38 million shares of worth about $0.46 million changed hands on the day. On Thursday the price saw a gain of about 13.21%. Currently the company’s common shares owned by public are about 30.83M shares, out of which, 8.50M shares are available for trading.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 5 times over the past 12 months. They bought 220,633 shares in 5 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Bellicum Pharmaceuticals Inc. Vanguard Total Stock Market Index is currently holding 0.27 million shares of worth totaling $0.19 million. The company recently came buying 0.0 shares which brought its stake up to 3.08% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 37318.0 shares, have now control over 0.43% of the stake in the company. It holds 0.0 shares of worth $26869.0.
Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM) started trading at $1.10, above $0.04 from concluding price of the previous day. However, the stock later moved at a day high price of 1.3600, or with a gain of 13.21%. Stock saw a price change of 21.19% in past 5 days and over the past one month there was a price change of 56.78%. Year-to-date (YTD), BLCM shares are showing a performance of 66.67% which decreased to -14.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.60 but also hit the highest price of $2.20 during that period. The average intraday trading volume for Bellicum Pharmaceuticals Inc. shares is 25.21K. The stock is currently trading 42.56% above its 20-day simple moving average (SMA20), while that difference is up 26.62% for SMA50 and it goes to -3.31% lower than SMA200.
Renaissance Technologies LLC acquired 13700.0 shares of Bellicum Pharmaceuticals Inc. having value of about $9864.0. Data submitted at the U.S SEC by Renaissance Technologies LLC revealed that the firm now holds 300.0 shares in the company valued at close to $360.0, or have control over 2.24% stake in the company. Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM) currently have 30.83M outstanding shares and institutions hold larger chunk of about 31.40% of that. Holding of mutual funds in the company is about 5.21% while other institutional holders and individual stake holders have control over 8.98% and 14.74% of the stake respectively.
The stock has a current market capitalization of $10.36M and its 3Y-monthly beta is at 1.40. It has posted earnings per share of -$0.45 in the same period. It has Quick Ratio of 5.40 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BLCM, volatility over the week remained 15.31% while standing at 16.07% over the month.
Analysts are in expectations that Bellicum Pharmaceuticals Inc. (BLCM) stock would likely to be making an EPS of -$0.64 in the current quarter, while forecast for next quarter EPS is -$0.66 and it is -$1.32 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.64 which is -$0.64 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.22 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 37.10% while it is estimated to increase by 26.60% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Bellicum Pharmaceuticals Inc. (BLCM)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on October 30, 2020 offering an Equal weight rating for the stock and assigned a target price of $4.50 to it. On April 12, 2018, Wells Fargo Upgrade their recommendations, while on April 12, 2018, Cantor Fitzgerald Reiterated their ratings for the stock with a price target of $18. Stock get an Overweight rating from Cantor Fitzgerald on January 31, 2018.
